Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings
Paris, France and Amsterdam, The Netherlands -- The Offeror, Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis today announce that the conversion of Kiadis from a public limited liability company (naamloze vennootschap) into a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) shall be postponed until the Offeror has completed the statutory buy-out proceedings.
In Section 6.13 of the Offer Memorandum the Offeror stated that it has the intention to amend the articles of association of Kiadis following termination of the listing of the Kiadis shares on Euronext Amsterdam and Euronext Brussel (which took place on 25 May 2021). On 30 March 2021, the general meeting of Kiadis adopted a shareholders' resolution to amend the articles of association as soon as possible following delisting. Upon reflection, the Offeror and Kiadis have decided to postpone the conversion of Kiadis into a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) until the buy-out proceedings have been completed.
Announcements
Any announcement contemplated by the Offer Memorandum will be issued by press release. Any press release issued by the Offeror will be made available on the website of the Offeror (www.sanofi.com). Any press release issued by Kiadis will be made available on the website (www.kiadis.com).
Subject to any applicable requirements of the applicable rules and without limiting the manner in which the Offeror may choose to make any public announcement, the Offeror will have no obligation to communicate any public announcement other than as described above.
Offer Memorandum, Position Statement and further information
This announcement contains selected, condensed information regarding the Offer and does not replace the Offer Memorandum and/or the position statement by Kiadis dated 12 February 2021 (the “Position Statement”). The information in this announcement is not complete and additional information is contained in the Offer Memorandum and the Position Statement.
Digital copies of the Offer Memorandum are available on the website of the Offeror (www.sanofi.com) and digital copies of the Position Statement are available on the website of Kiadis (www.kiadis.com). Such websites do not constitute part of, and are not incorporated by reference into, the Offer Memorandum. Copies of the Offer Memorandum and the Position Statement are on request also available free of charge at the offices of Kiadis and the Settlement Agent at the addresses below:
Kiadis
Kiadis Pharma N.V.
Paasheuvelweg 25A
1105 BP Amsterdam
The Netherlands
Settlement Agent
ING Bank N.V.
Bijlmerdreef 106
1102 CT Amsterdam The Netherlands
For more information:
Sanofi Media Relations Contact
Ashleigh Koss
Tel.: +1 (908) 205 2572
ashleigh.koss@sanofi.com
Sanofi Investor Relations Contacts Paris
Eva Schaefer-Jansen
Arnaud Delepine
Yvonne Naughton
Sanofi Investor Relations Contacts North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco
IR main line:
Tel.: +33 (1) 53 77 45 45
ir@sanofi.com
About Kiadis
Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life- threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. Sanofi prevents illness with vaccines and provides innovative treatments to fight pain and ease suffering. Sanofi stands by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life.
-
Most popular related searches
Customer comments
No comments were found for Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings. Be the first to comment!